Please use this identifier to cite or link to this item:
Title: Plasma acylcarnitines and risk of cardiovascular disease: effect of Mediterranean diet interventions.
Authors: Guasch-Ferré, Marta
Zheng, Yan
Ruiz-Canela, Miguel
Hruby, Adela
Martínez-González, Miguel A
Clish, Clary B
Corella, Dolores
Estruch, Ramon
Ros, Emilio
Fitó, Montserrat
Dennis, Courtney
Morales-Gil, Isabel M
Arós, Fernando
Fiol, Miquel
Lapetra, José
Serra-Majem, Lluís
Hu, Frank B
Salas-Salvadó, Jordi
Keywords: Mediterranean diet;PREDIMED;acylcarnitines;cardiovascular disease;metabolomics
metadata.dc.subject.mesh: Aged
Body Mass Index
Cardiovascular Diseases
Cohort Studies
Diet, Mediterranean
Middle Aged
Prospective Studies
Risk Factors
Issue Date: 20-Apr-2016
Abstract: Previous studies have suggested that metabolite profiles of elevated acylcarnitines were associated with increased risk of cardiovascular disease (CVD) in populations with established coronary disease. However, to our knowledge, this association has not been evaluated in the context of primary cardiovascular prevention. We evaluated the association between 28 plasma acylcarnitine species and risk of incident CVD and the potential modifying effect of Mediterranean diet (MedDiet) interventions. We measured plasma acylcarnitines with the use of high-throughput liquid chromatography-tandem mass spectrometry at baseline and after 1 y of follow-up, both individually and classified into short-, medium-, or long-chain scores, in a case-cohort study within the Prevención con Dieta Mediterránea (PREDIMED) study, which is a randomized Mediterranean dietary intervention for primary cardiovascular prevention. A randomly selected subcohort (n = 751) and all available incident CVD cases (n = 229) after 4.8 y of follow-up were included in the current study. After adjustment for age, sex, body mass index, and other CVD risk factors, participants in the highest quartile of baseline short- and medium-chain acylcarnitines had a higher risk of CVD than did participants in the lowest quartile [HRs: 1.80 (95% CI: 1.11, 2.91; P-trend 0.01) and 1.55 (95% CI: 1.01, 2.48; P-trend = 0.04), respectively]. Increased short-chain acylcarnitines after 1 y were associated with higher risks of total CVD and stroke. Participants with higher baseline concentrations of short-, medium-, and long-chain acylcarnitines who were randomly assigned to the control group had a higher risk of CVD than did subjects with lower concentrations of acylcarnitines who were assigned to the MedDiet group. Our data support the conclusion that metabolite profiles characterized by elevated concentrations of acylcarnitines are independently associated with risks of total CVD and stroke alone in participants at high risk of CVD. MedDiet interventions may mitigate the adverse associations shown between higher concentrations of acylcarnitines and CVD. This trial was registered at as ISRCTN35739639.
metadata.dc.identifier.doi: 10.3945/ajcn.116.130492
Appears in Collections:Producción 2020

Files in This Item:
There are no files associated with this item.

This item is protected by original copyright

Except where otherwise noted, Items on the Andalusian Health Repository site are licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives License.